Ticker

The iShares Biotechnology ETF carries a lower expense ratio and significantly larger assets under management (AUM) than the Simplify Health Care ETF. The Simplify Health Care ETF provides broader exposure across healthcare sub-sectors and a higher dividend yield than the biotechnology-focused iShares fund.

Envestnet Asset Management Inc. decreased its stake in iShares Biotechnology ETF (NASDAQ: IBB) by 8.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,122,659 shares of the financial services provider's stock after selling 104,009 shares during

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

The Nasdaq 100 carved out a fresh intraday record by midday Tuesday as the artificial intelligence trade powered ahead.

NewEdge Advisors LLC raised its stake in iShares Biotechnology ETF (NASDAQ: IBB) by 33.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,622 shares of the financial services provider's stock after acquiring an additional 4,888 shares during the period.